Second-line treatment options in hepatocellular carcinoma

• Príomhchruthaitheoirí: Donatella Marino (Údar), Clizia Zichi (Údar), Marco Audisio (Údar), Elisa Sperti (Údar), Massimo Di Maio (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: BioExcel Publishing Ltd, 2019-04-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed to prove any survival benefit. However, in the...